Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25475012)

  • 1. YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines.
    Sachita K; Yu HJ; Yun JW; Lee JS; Cho SD
    J Oral Pathol Med; 2015 Nov; 44(10):785-91. PubMed ID: 25475012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells.
    Feng W; Yoshida A; Ueda T
    Biochem Biophys Res Commun; 2013 May; 435(1):52-7. PubMed ID: 23618862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.
    Yan X; Su H
    Med Sci Monit; 2017 Apr; 23():1963-1972. PubMed ID: 28435150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
    Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
    Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
    Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
    Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells.
    Woo SM; Min KJ; Seo BR; Kwon TK
    Oncotarget; 2016 Sep; 7(38):61520-61532. PubMed ID: 27528031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.
    Cheng SM; Chang YC; Liu CY; Lee JY; Chan HH; Kuo CW; Lin KY; Tsai SL; Chen SH; Li CF; Leung E; Kanwar JR; Huang CC; Chang JY; Cheung CH
    Br J Pharmacol; 2015 Jan; 172(1):214-34. PubMed ID: 25220225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.
    Kojima Y; Hayakawa F; Morishita T; Sugimoto K; Minamikawa Y; Iwase M; Yamamoto H; Hirano D; Imoto N; Shimada K; Okada S; Kiyoi H
    Pharmacol Res; 2017 Jun; 120():242-251. PubMed ID: 28396094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells.
    Chiou JT; Lee YC; Huang CH; Shi YJ; Wang LJ; Chang LS
    Toxicol Appl Pharmacol; 2020 Jan; 387():114857. PubMed ID: 31837377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.
    Tang H; Shao H; Yu C; Hou J
    Biochem Pharmacol; 2011 Nov; 82(9):1066-72. PubMed ID: 21784061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells.
    Woo SM; Min KJ; Seo BR; Seo YH; Jeong YJ; Kwon TK
    Mol Cell Biochem; 2017 May; 429(1-2):91-102. PubMed ID: 28120212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
    Zhang S; Wang X; Gu Z; Wang L
    Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary study of biological mechanism and apoptotic effect induced by YM155 in SUDHL-4 cell line].
    Liang W; Zhang WJ; Gao QM; Qin W; Lu HN; Huang BB; Xiu B; Liang AB
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(10):700-4. PubMed ID: 22781300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.
    Tao YF; Lu J; Du XJ; Sun LC; Zhao X; Peng L; Cao L; Xiao PF; Pang L; Wu D; Wang N; Feng X; Li YH; Ni J; Wang J; Pan J
    BMC Cancer; 2012 Dec; 12():619. PubMed ID: 23267699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.
    Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP
    Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML sensitivity to YM155 is modulated through AKT and Mcl-1.
    de Necochea-Campion R; Diaz Osterman CJ; Hsu HW; Fan J; Mirshahidi S; Wall NR; Chen CS
    Cancer Lett; 2015 Sep; 366(1):44-51. PubMed ID: 26118775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
    Chiou JT; Lee YC; Huang CH; Wang LJ; Shi YJ; Chang LS
    Biochem Pharmacol; 2021 Jun; 188():114544. PubMed ID: 33831396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells.
    Jung SA; Park YM; Hong SW; Moon JH; Shin JS; Lee HR; Ha SH; Lee DH; Kim JH; Kim SM; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Jin DH; Kim T
    J Biol Chem; 2015 Apr; 290(16):9974-85. PubMed ID: 25635055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
    Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
    Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.